Loading…
Creative Medical Technology Holdings, Inc. is projected to rise to $1.09 by 2027, a +19% move from its current price of $0.9121. CELZ is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.8455 | $0.9125 | $0.9847 | +0.04% |
| Jul 15 | $0.8195 | $0.9128 | $1.02 | +0.08% |
| Jul 16 | $0.8002 | $0.9132 | $1.04 | +0.12% |
| Jul 17 | $0.7844 | $0.9135 | $1.06 | +0.16% |
| Jul 18 | $0.7707 | $0.9139 | $1.08 | +0.20% |
| Jul 19 | $0.7585 | $0.9143 | $1.10 | +0.24% |
| Jul 20 | $0.7476 | $0.9146 | $1.12 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7476 | $0.9146 | $1.12 | +0.28% |
| Week 2 | $0.6896 | $0.9171 | $1.22 | +0.55% |
| Week 3 | $0.6485 | $0.9197 | $1.30 | +0.83% |
| Week 4 | $0.6161 | $0.9222 | $1.38 | +1.11% |
| Week 5 | $0.5891 | $0.9247 | $1.45 | +1.38% |
| Week 6 | $0.5658 | $0.9273 | $1.52 | +1.66% |
| Week 7 | $0.5454 | $0.9298 | $1.59 | +1.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. It offers CaverStem to treat erectile dysfunction and FemCelz for the treatment of loss of genital sensitivity and dryness, and it is developing a broad pipeline that includes AlloStem (CELZ-201-DDT) and ImmCelz (CELZ-100), CELZ-201 CREATE-1 for type 1 diabetes (phase 2), AlloStemSpine (CELZ 201 ADAPT) for chronic lower back pain, Alova for infertility, StemSpine, OvaStem, and other platforms.
The company also pursues products and services aimed at preventing organ transplant rejection and treating kidney failure, liver failure, heart attack, and Parkinson’s disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings, Inc. (CELZ) is traded with a current price of $0.9121 and a market capitalization of $5.92M, ranking 5224. The stock sits in the Healthcare sector and carries a history of a volatile price trajectory reflected in its 30-day range and technical indicators.
The stock’s near-term setup shows a bearish tilt, while long-run forecasts depict a path of potential upside with varying annual returns.
A major floor 11.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.2% below — buyers have tended to step in here.
The nearest ceiling, 162.0% above — a clean break opens room to run.
A major ceiling 223.5% above — clearing it would confirm fresh momentum.
Key CELZ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CELZ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.02 | Sell | $1.02 | Sell |
| MA 10 | $1.10 | Sell | $1.19 | Sell |
| MA 20 | $1.62 | Sell | $1.47 | Sell |
| MA 50 | $1.99 | Sell | $1.81 | Sell |
| MA 100 | $2.00 | Sell | $2.00 | Sell |
| MA 200 | $2.35 | Sell | $2.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.07 | Neutral |
| Stoch RSI (14) | 56.10 | Neutral |
| CCI (20) | -91.51 | Neutral |
| Williams %R (14) | -91.44 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -53.70 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 8.56 | Buy |
| TRIX (15) | -1.81 | Sell |
| Awesome (5,34) | -0.85 | Sell |
| Ultimate (7,14,28) | 11.86 | Buy |
| Momentum (10) | -1.09 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.90 | Buy |
| ADX (14) | 25.80 | Sell |
| ATR (14) | 0.13 | Info |
The 30-day technical picture shows a Bearish sentiment with RSI(14) at 30. The stock trades around the simple moving averages, with SMA50 at $1.99 and SMA200 at $2.35, suggesting the shorter-term average is below the longer-term average. The nearby support is at $0.8102 and resistance at $2.39, framing a 30-day range from $0.5519 to $1.51.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.8102 | $0.9121 | $1.39 | 0% | Neutral | |
| $0.788 | $1.09 | $1.62 | +19% | Neutral | |
| $0.7659 | $1.12 | $1.78 | +23% | Bullish | |
| $0.6752 | $1.04 | $1.74 | +14% | Neutral | |
| $0.5115 | $0.8273 | $1.44 | -9% | Neutral | |
| $0.5972 | $1.01 | $1.81 | +11% | Neutral | |
| $0.6421 | $1.13 | $2.10 | +24% | Bullish | |
| $0.6879 | $1.26 | $2.41 | +39% | Bullish | |
| $0.8439 | $1.61 | $3.15 | +77% | Bullish | |
| $0.7561 | $1.50 | $3.00 | +65% | Bullish | |
| $0.9939 | $2.21 | $4.85 | +142% | Bullish | |
| $1.34 | $2.98 | $6.85 | +227% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.8102 | $0.9121 | $1.18 | +0.00% |
| August 2026 | $0.8175 | $0.9901 | $1.25 | +8.55% |
| September 2026 | $0.7696 | $0.9454 | $1.22 | -4.52% |
| October 2026 | $0.7814 | $0.9716 | $1.27 | +2.78% |
| November 2026 | $0.8263 | $1.04 | $1.38 | +6.85% |
| December 2026 | $0.8113 | $1.03 | $1.39 | -0.85% |
Click any year to see its month-by-month CELZ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Creative Medical Technology Holdings, Inc.'s 2026 outlook centres on $0.9121, within a $0.8102 to $1.39 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CELZ could reach as high as $1.62, with a base case around $1.09 and support toward $0.788 — roughly +19% from $0.9121. Price action looks broadly range-bound.
Expect CELZ to range from $0.7659 to $1.78 through 2028. The $1.12 average target implies a +23% move from current prices. That is up +3% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CELZ price prediction for 2029 points to an average of $1.04 (low $0.6752, high $1.74) — a potential gain of +14% on today's $0.9121. Price action looks broadly range-bound.
In 2030, CELZ is projected to trade between $0.5115 and $1.44, averaging $0.8273 — a potential decline of -9% from today's $0.9121. That is -21% versus the projected 2029 average. A consolidation phase looks the most probable path here.
Creative Medical Technology Holdings, Inc.'s 2031 outlook centres on $1.01, within a $0.5972 to $1.81 range. That is up +22% on the projected 2030 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2032, CELZ could reach as high as $2.10, with a base case around $1.13 and support toward $0.6421 — roughly +24% from $0.9121. Buyers look set to stay in control over this stretch.
Expect CELZ to range from $0.6879 to $2.41 through 2033. The $1.26 average target implies a +39% move from current prices. That is up +12% on the projected 2032 average. Momentum favours further upside here.
The CELZ price prediction for 2034 points to an average of $1.61 (low $0.8439, high $3.15) — a potential gain of +77% on today's $0.9121. Buyers look set to stay in control over this stretch.
In 2035, CELZ is projected to trade between $0.7561 and $3.00, averaging $1.50 — a potential gain of +65% from today's $0.9121. That is -7% versus the projected 2034 average. Momentum favours further upside here.
Creative Medical Technology Holdings, Inc.'s 2040 outlook centres on $2.21, within a $0.9939 to $4.85 range. That is up +47% on the projected 2035 average. That marks a +142% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CELZ could reach as high as $6.85, with a base case around $2.98 and support toward $1.34 — roughly +227% from $0.9121. Momentum favours further upside here.
Investing $1,000 in CELZ today (≈ 1,096.371012 CELZ) could be worth
$3,265.02
+$2,265.02 (+227%) by 2050 · US Dollar
Based on the average projected CELZ price of $2.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CELZwould be worth at today's price.
$1,000 invested in CELZ on Jul 10, 2025 (≈ 348.43207 CELZ) would be worth
$317.8
-$682.2 (-68.2%) today · 0.32× · US Dollar
Based on a CELZ entry price of $2.87 vs. today's $0.9121.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.21 | $753.8 | -24.6% |
| 1 month ago | $2.11 | $432.27 | -56.8% |
| 3 months ago | $2.14 | $426.21 | -57.4% |
| 6 months ago | $2.05 | $444.93 | -55.5% |
| 1 year ago | $2.87 | $317.8 | -68.2% |
| All time (5.0y) ago | $165 | $5.53 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CELZ forecast.
Our base-case forecast reaches $1.80 around 2040.
Implied market cap at $1.80: $11.68M
Over the multi-year horizon, the forecast projects varied annual averages and returns. The 2026 average is $0.9121 with a 0% ROI and Neutral sentiment; 2027 shows an average of $1.09 with 19.3% ROI and Neutral sentiment; 2028’s average is $1.12 with 23% ROI and Neutral to Bullish tilt; 2029’s average is $1.04 with 13.9% ROI. In 2030 the average is $0.8293 with -9.1% ROI and Neutral sentiment, followed by 2031 at $1.01 with 10.8% ROI; 2032 at $1.13 with 23.9% ROI; 2033 at $1.26 with 38.7% ROI; 2034 at $1.61 with 76.9% ROI; and 2035 at $1.50 with 64.4% ROI.
The long-range forecast rises to $2.21 average in 2040 (142.4% ROI) and $2.97 average in 2050 (225.8% ROI), with Bullish sentiment from 2032 onward. These figures imply meaningful upside potential over the coming years, albeit with notable downside risk including a negative ROI in 2030. The max price forecasts reach as high as $6.84 by 2050, underscoring substantial upside if these scenarios materialize, while the price path remains sensitive to shifts in market conditions and execution.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $0.5127, an avg of $0.8293, and a max of $1.44 with a ROI of -9.1% and Neutral sentiment.
Yes. The max forecasts show $2.09 in 2032 and $2.41 in 2033, indicating it could exceed $2 by 2032–2033. Longer-horizon max forecasts rise to $4.85 (2040) and $6.84 (2050).
Current price is $0.9121 and market capitalization is $5.92M.
The 2027 average is $1.09 with a min of $0.7894, a max of $1.62, and a 19.3% ROI, with Neutral sentiment.
Bearish sentiment with RSI(14) at 30. SMA50 is $1.99 and SMA200 is $2.35. The 30-day range is $0.5519 to $1.51, with support at $0.8102 and resistance at $2.39.
Creative Medical Technology Holdings, Inc. Community Discussion
0Share your Creative Medical Technology Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.